Vigabatrin monotherapy for infantile spasms

Area of Science:

• Neurology
• Pediatric Epilepsy
• Pharmacology

Background:

• Infantile spasms syndrome (IS), or West syndrome, is a severe epileptic encephalopathy with diverse causes.
• Tuberous sclerosis is a frequent underlying condition, identified in approximately 10% of infants with IS.
• Hormonal therapies like ACTH and steroids have historically been primary treatments for IS.

Purpose of the Study:

• To evaluate the efficacy of vigabatrin in treating infantile spasms.
• To assess vigabatrin's role as a first-line therapy, particularly in cases associated with tuberous sclerosis.
• To analyze the risk-benefit profile of vigabatrin, considering its efficacy against potential adverse effects.

Main Methods:

• Review of clinical studies comparing vigabatrin to placebo for infantile spasms treatment.
• Analysis of vigabatrin's mechanism of action, focusing on GABAergic neurotransmission.
• Examination of the incidence and severity of vigabatrin's adverse effects, specifically visual field constriction.

Main Results:

• Vigabatrin demonstrated superior efficacy over placebo in reducing the frequency of infantile spasms.
• In tuberous sclerosis-associated IS, vigabatrin emerged as a potential first-line treatment option.
• A significant adverse effect of vigabatrin is permanent visual field constriction, occurring in 6-7% of patients.

Conclusions:

• Vigabatrin is an effective treatment for infantile spasms, offering a significant reduction in seizure frequency.
• The decision to use vigabatrin necessitates a careful balance between its therapeutic benefits and the risk of irreversible visual impairment.
• Vigabatrin's efficacy, particularly in tuberous sclerosis, positions it as a key therapeutic agent, albeit with critical safety considerations.